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The use of complementary and alternative Medicine (CAM) has increased over the past two decades in Europe.
Nonetheless, research investigating the evidence to support its use remains limited. The CAMbrella project funded
by the European Commission aimed to develop a strategic research agenda starting by systematically evaluating
the state of CAM in the EU. CAMbrella involved 9 work packages covering issues such as the definition of CAM; its
legal status, provision and use in the EU; and a synthesis of international research perspectives. Based on the work
package reports, we developed a strategic and methodologically robust research roadmap based on expert
workshops, a systematic Delphi-based process and a final consensus conference. The CAMbrella project suggests six
core areas for research to examine the potential contribution of CAM to the health care challenges faced by the EU.
These areas include evaluating the prevalence of CAM use in Europe; the EU cititzens’ needs and attitudes regarding
CAM; the safety of CAM; the comparative effectiveness of CAM; the effects of meaning and context on CAM out-
comes; and different models for integrating CAM into existing health care systems. CAM research should use
methods generally accepted in the evaluation of health services, including comparative effectiveness studies and
mixed-methods designs. A research strategy is urgently needed, ideally led by a European CAM coordinating
research office dedicated to fostering systematic communication between EU governments, the public, charitable
and industry funders, researchers and other stakeholders. A European Centre for CAM should also be established to
monitor and further a coordinated research strategy with sufficient funds to commission and promote high quality,
independent research focusing on the public’s health needs and pan-European collaboration. There is a disparity
between highly prevalent use of CAM in Europe and solid knowledge about it. A strategic approach on CAM
research should be established to investigate the identified gaps of knowledge and to address upcoming health
care challenges.
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Complementary and alternative medicine (CAM) in the
European Union (EU) includes practices such as acu-
puncture, anthroposophic medicine, aromatherapy,
herbal medicine, homeopathy, kinesiology, massage, na-
turopathy, shiatsu, traditional Chinese medicine, and
yoga. Over the last 25 years, the use of CAM has risen
in Western industrialized countries [1-4] and CAM has
been used often by patients with chronic conditions,
such as cancer or chronic pain, or in situations where
conventional treatment options have been limited [5].
The new EU framework programme ‘Horizon 2020’
emphasizes the consequences of demographic change in
the EU, focusing in particular on elderly patients, who
often experience multiple, chronic conditions. CAM
may therefore have an important role to play in improv-
ing health and well-being in an ageing EU population,
including the management of chronic conditions, the
prevention of illness, and the promotion of health. Due
to substantial gaps in knowledge about CAM, the pre-
cise role of CAM in these areas remains unclear.
In 2009 the European Commission called for coordi-
nated and collaborative efforts to assess the current state
of CAM in Europe in terms of definition, legal status,
prevalence, provision and the attitudes of EU citizens as
well as to identify the best methodological and strategic
approaches to research in this field. The coordination
project CAMbrella included 16 institutions from 12
European countries (Figure 1) and was funded by the
7th Framework Programme to address these issues in a
systematic manner [6].
Based on the findings of this assessment, a roadmap
was developed to point out which areas of CAM re-
search appear promising, which methods should be ap-
plied, and how the EU could foster a more coordinated
approach. Our suggestions are limited to the field of
clinical and epidemiological research. Basic research - al-
though also of great relevance - is not addressed within
CAMbrella. The recommendations made as part of the
roadmap are based on the knowledge and experience of
European and international researchers in the field, and
are designed to improve the quality and methodology of
CAM research, as well as its relevance to clinical deci-
sion making.
The aim of this article is to present the CAMbrella re-
search roadmap based on the key results of the main
CAMbrella work packages to a wider audience of scien-
tists, health care providers, decision makers and the
public.
Methods
The CAMbrella roadmap includes strategic and meth-
odological recommendations for future CAM research
and was developed systematically over three years(2010–12) (Figure 2). Within each CAMbrella work
package, we used different methods to answer the ques-
tions raised, including systematic reviews, qualitative
data analysis, workshops, focus groups, qualitative data
synthesis, Delphi consensus techniques, and expert con-
ferences. In particular, the CAMbrella group conducted
four systematic reviews to describe the current state of
legislation pertaining to CAM in the EU [7], citizens’
and patients’ attitudes and needs regarding CAM [8],
the prevalence of CAM use [9], and key issues in clinical
and epidemiological research on CAM [10]. Further-
more, CAM definitions and terminology were analysed
and a pragmatic definition of CAM was developed [11].
We also evaluated the current state of CAM provision
in the EU [12]. Lastly, international perspectives on
CAM research were assessed as part of a qualitative
study that included experts and organizations from Asia,
Australia, Europe and North America [13] (Table 1).
These studies served as the basis for a three-day expert
workshop on CAM research strategies and methods,
which took place in Castellaro, Italy, from September 7-
9, 2011. A draft of the recommendations was developed
and finalized in two written Delphi rounds between
January and March 2012. The final draft was sent to all
members of the CAMbrella consortium and to the
CAMbrella advisory board in April 2012 for feedback. A
revised version was presented at a one-day consensus
conference, which took place in Järna, Sweden, on May
10, 2012. The roadmap was revised following the sugges-
tions of the participants in the consensus conference
and ultimately approved by CAMbrella’s Scientific Steer-
ing Committee in September 2012.
A total of 36 experts participated in the process,
including all members of the CAMbrella consortium
(n = 24, from 12 different European countries) (Figure 1);
the CAMbrella Advisory Board (n = 7, from 5 European
countries), which consisted of CAM doctors, practi-
tioners, patient advocates and manufacturers; and 5 ex-
ternal, internationally recognized experts on CAM
research methodology from the USA (1), the UK (2) and
Germany (2).
Findings
The CAMbrella vision for the year 2020 is that research
into CAM will provide a broad but relevant and compre-
hensive evidence base, enabling the EU public and health
care providers to make informed decisions about CAM
use, both for individuals and for society as a whole.
A main issue is to define clinical situations in which
CAM treatment is appropriate. The CAMbrella roadmap
puts forward a research agenda for CAM that is de-
signed to address future health care challenges in the
EU. In particular, these include the increasing prevalence
of chronic conditions and ongoing financial constraints.
Figure 1 The CAMbrella Consortium funded by Framework Program 7.
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CAMbrella roadmap provides an outline for quantitative
and qualitative research, suggesting six core areas cover-
ing important gaps in knowledge (Table 2). Hence, the
roadmap also suggests a methodological framework for
future CAM research based on the experiences of the
past and makes a range of recommendations on steps
the EU could take to foster these efforts.
Research into the prevalence of CAM use
Our systematic review of the prevalence of CAM use in
the EU concluded that the included studies were too
heterogeneous in terms of definitions and methodo-
logical rigor to draw even a tentative picture [9]. The
lifetime prevalence of CAM use ranged from 0.3% to
86% in the populations studied, and data for more than
half of the EU member states were lacking entirely. Data
from our evaluation of CAM provision suggest that
there may be roughly 300,000 providers of CAM in itsvarious forms practicing within the EU, of whom ap-
proximately 60% are non-medical providers [12].
A clear picture of CAM use is crucial for providers,
purchasers and health policy makers alike. We recom-
mend that the prevalence of CAM use in the EU be
assessed using large, cross-sectional studies. A consistent
approach that allows meaningful comparisons of CAM
prevalence across EU member states needs to be based
on a clearly defined set of common CAM practices and
treatments. A common survey methodology, including
standardized questionnaires translated into the various
national languages, is essential to ensure the comparabil-
ity of data. This approach must also be based on the
principles of good epidemiological research [14].
Citizens’ attitudes and needs regarding CAM
Data on citizens’ attitudes and needs regarding CAM
are very limited, with information available for fewer
than half of the EU member states. Moreover, the
Figure 2 Roadmap development process.
Fischer et al. BMC Complementary and Alternative Medicine 2014, 14:46 Page 4 of 9
http://www.biomedcentral.com/1472-6882/14/46methodology and results of previous studies have been
poorly reported. Most of the research conducted to date
has been drawn from UK samples, and only a few stud-
ies have focused specifically on citizens’ needs [8]. The
results of these studies indicate that patients often
choose CAM because they are unsatisfied with conven-
tional medical treatments [8,9]. Furthermore, compared
to other stakeholders in the health sector, patients ap-
pear to value different aspects of CAM practice, making
their involvement in CAM research crucial. An import-
ant aspect of our findings was that the EU public ur-
gently needs more reliable and accessible information
about CAM [8,15]. These attitudes and needs have been
taken into account and are reflected in the roadmap. In
addition, EU citizens’ and patients’ attitudes and needs
should be considered in CAM research by disseminating
information about CAM and assessing the outcomes of
CAM treatment from the patients’ perspective.
A structured approach to CAM research that is rele-
vant to the public’s needs requires comparable data from
all EU member states so that studies can be conducted
in parallel in several countries whenever possible. Exam-
ples of such approaches include:
 large scale surveys based on validated
questionnaires;
 qualitative interviews and fieldwork studies with
in-depth explorations of local experiences and
practice; and interdisciplinary research involving mixed-methods
with CAM providers and clients as research
partners.
Safety
People take the safety in account when they make deci-
sions about CAM [8]. The considerable differences in
the definitions [11], regulation [7] and provision [12] of
CAM mean that overarching statements about its safety
are inadequate. Furthermore, most CAM treatments
have been developed over very long periods and have
not undergone robust safety evaluation prior to use [16].
Although safety has also been an important issue among
CAM researchers over the past decade [10], it is still
poorly understood. A detailed understanding of these is-
sues and the ability to compare treatments based on
their risk-benefit ratios are crucial if stakeholders are to
make appropriate decisions regarding the use of CAM.
In addition, because CAM is often used alongside con-
ventional or other non-conventional medical treatments,
special attention must be paid to the potential for treat-
ment interactions.
We suggest addressing CAM safety on a regular basis.
Data from clinical trials should be routinely used to in-
vestigate the frequency of the more common side ef-
fects, since comparisons to adequate control groups help
establish risk-benefit ratios. The reporting of serious side
effects in single case studies should be fostered. In the
long run, developing a European monitoring system for
Table 1 Work packages within the CAMbrella project
Work package Lead institution Goal Methods Reference
WP1 University of Zurich Definition of CAM Expert consensus panel [11]
WP2 University of Tromsø Legal status Systematic review of legislative documents [7]
WP3 University of Southern Denmark, Odense Citizens’ perspective Systematic review of scientific literature [8]
WP4 University of Southampton Patients’ perspective Systematic review of scientific literature [9]
WP5 University of Bern Providers’ perspective Review of scientific literature/grey literature
and personal communication with key
stakeholders
[12]
WP6 Karolinska Institutet, Stockholm International perspective Interviews with key international institutions [13]
WP7 Charité University Medical Center, Berlin Research methods Systematic review of scientific literature [10]
WP8 International Academy for Holistic Medicine,
Vienna
Dissemination and
communication
- [15]
WP9 Technische Universität München Project coordination - [6]
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thorough information about CAM prevalence and
provision.
Comparative effectiveness research
One of the main strategic questions in CAM research
has been whether to prioritize the evaluation of specific
effects of single elements of a multi-component treat-
ment (i.e., efficacy) or to investigate the overall treat-
ment effects in more pragmatic clinical settings (i.e.,
effectiveness) [10]. Patients and providers need to know
when CAM is a reasonable choice, as this enables them
to make informed decisions in real-world situations. Un-
fortunately, clinical research to date has often focused
on the specific effects of CAM in ideal and standardized
clinical situations that are rarely experienced in clinicalTable 2 Overview of key research in the CAMbrella research r
Key research areas Aim Recomm
CAM prevalence To obtain valid, comparable
and comprehensive data on
prevalence of CAM use
Structured
approach
Needs and attitudes of
citizens and providers
To address issues that are
relevant to the EU public
Obtain da
diversity o
influences
CAM
CAM safety To allow the risks of CAM
to be estimated
Address s
and estab
monitorin
Comparative effectiveness
research
To support clinical and health
care policy decision making
with suitable research data
Future res
primarily i
in real-wo
Effects of context and
meaning
Understand the extent to
which the clinical effects of
CAM are due to non-specific
treatment effects
Assess the
influence
specific tr
Models of CAM integration To investigate different models
of CAM integration
Describe,
further de
CAM integpractice. Therefore, there is a strong need to investigate
neglected real-world scenarios in clinical research.
Current trends in conventional medicine also address
the limited impact of efficacy studies on decision making
in clinical practice [17]. In response, standards for
patient-centred outcomes research are currently being
developed internationally [18]. The movement in con-
ventional medicine towards more comparative effective-
ness research has focused strongly on evaluating
different treatment options by including a more hetero-
geneous patient sample, using real-world treatment
protocols that are less standardized focusing on patient-
centred outcomes [19,20].
The advantage of comparative effectiveness research is
its capacity to evaluate CAM as an optional add-on to
conventional treatment, or as an alternative to it. Suchoadmap
endation Research methods Specifics
EU-wide Cross-sectional studies Using standard definitions,
develop standardized
questionnaires for surveys
in European languages
ta on how the
f the EU
attitudes about
Cross-sectional studies;
qualitative interview
studies
Involve the public as
stakeholders in project
development
afety in studies
lish an EU-wide
g system
Observational studies;
clinical studies; single
case studies
Clarify safety terminology;
address safety in CAM
studies where appropriate
earch should
nvestigate CAM
rld settings
Comparative
effectiveness research,
including pragmatic
clinical trials
Compare meaningful
alternatives; include health
economic evaluations
nature, size and
of potential non-
eatment effects
Mixed methods
(qualitative studies
within clinical trials)
Research question is not
specific to CAM, but of
general interest
evaluate and
velop models for
ration
Mixed methods Include the public’s view
on models of CAM
integration
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ventions, medium and long-term clinical effects, and
cost-effectiveness in comparison to treatment alterna-
tives. Furthermore, comparative effectiveness research
calls for stakeholder involvement to help ensure external
validity and relevance [21].
Research in real-world settings is the most promising
approach to identifying the possible contributions of a
variety of modalities, such as CAM, to the health of the
EU public. Future research on CAM should emphasize
comparative effectiveness analysis as a way to obtain
data that are valuable to all stakeholders and provide
useful guidance in a pragmatic clinical context.
Context and meaning effects
There is an on-going debate about the nature, size and
relevance of clinical effects in CAM. It has been repeat-
edly pointed out that CAM interventions seem to be as-
sociated often with strong context and meaning effects
[10,22]. These so-called non-specific effects sometimes
seem to be more powerful than specific effects, such as
those elicited by needling a particular point in acupunc-
ture [23]. Therefore, despite small or even non-existent
specific effects some CAM interventions seem to be
clinically as effective or even more effective than
guideline-based conventional treatments [24,25]. The
context in which CAM treatments are provided appears
to be important to patients, who may choose CAM be-
cause of the patient-provider relationship [9] or their be-
liefs about a treatment [8]. Some methods have been
suggested for distinguishing between specific and non-
specific effects [10], but most CAM treatments, and
indeed most clinical practice, cannot be reduced to a
single therapeutic ingredient [26]. In combination, fac-
tors such as setting, diagnosis and personal interactions
are likely to be responsible in part for the treatment out-
come. We therefore see a strong need for research inves-
tigating how, and the extent to which, these factors
influence outcomes.
Valid and reliable tools are needed to assess compo-
nents of meaning and context effects, as doing so will fa-
cilitate clinical research and allow study results to be
compared. Special emphasis should be placed on the
question of whether CAM is associated with effects that
are different from those in conventional medicine. Un-
derstanding the mechanisms behind these effects will
help in identifying the appropriate scope and limits of
CAM, as well as those of conventional medical treat-
ments. Such research could lead to a better understand-
ing of the mechanisms underlying CAM, clarify the
value of CAM for patients and the general public, and
help politicians when making reimbursement decisions.
Patient and provider expectations, and the time required
for diagnosis and treatment, are examples of context andmeaning effects that should be included in clinical re-
search on CAM. Researchers should attempt to differen-
tiate these from the intrinsic impact of any specific
intervention. However, given the importance of context
and meaning effects in all fields of medicine, we believe
that research into this area should be a priority in
general.
Health care integration
There are many different CAM modalities and treat-
ments in the EU, as well as a wide variety of ways in
which CAM is provided to patients [7,12]. For example,
approaches to integrating CAM into health care systems
have been described as “opposition”, “integration” and
“pluralism” models. In some European countries, CAM
is provided as a private service and is often unregulated.
In other countries, the education and training of CAM
providers are regulated, as is the provision of CAM ser-
vices [12]. In yet other countries, some CAM treatments
are even provided within the public health care system
at the national or regional level, and in some cases is re-
imbursed by public payers. In general, however, the ac-
cessibility of CAM remains a major issue for the EU
public [8].
The various models of CAM provision in the EU are
likely to affect health care in different ways. Provision
outside of publicly funded health care allows a free
choice of treatments and respects the freedom of indi-
viduals within the EU as providers or users of CAM.
However, safety and equity of access might be easier to
achieve in countries where CAM is provided within the
public healthcare system.
At the moment, there is no consensus about the best
model for integrating effective CAM treatment, such as
acupuncture for pain, into the health care system. Also,
it is unlikely that there is one model that can fit all the
needs of the different regulatory systems. We recom-
mend evaluating concurrently the various existing
models of CAM integration to identify their strengths
and limitations. Furthermore, innovative models of
CAM provision should be developed to address the
needs of the public appropriately.
Methodological considerations
There is broad consensus in the scientific literature that
commonly accepted research methods in conventional
medicine can and should also be applied to CAM [10].
Quantitative approaches, such as observational studies
and randomized controlled trials, are needed to answer
questions about prevalence, safety, effectiveness, efficacy
and cost-effectiveness. At the same time, qualitative re-
search is needed to help us understand what really hap-
pens in CAM treatments, what outcomes are of interest
to the public when choosing CAM, and how CAM
Fischer et al. BMC Complementary and Alternative Medicine 2014, 14:46 Page 7 of 9
http://www.biomedcentral.com/1472-6882/14/46practitioners perceive their individual practice. We see
qualitative and quantitative methods not as competing,
but as complementary.
Potential users of CAM, policy makers, health care
providers, and health care payers should be involved at
each stage in the development of research questions and
study design. Involving stakeholders helps ensure the
real-world relevance of CAM research and, when done
in a systematic and transparent manner, improves the
impact of this research on health care systems. In
addition, qualitative methods, such as interviews and
focus groups, and quantitative methods, such as surveys,
can be useful in assessing stakeholders’ perspectives
systematically.
Effective criteria for selecting CAM treatments for fu-
ture research on prevalence of use, expected impact on
clinical practice, and overall feasibility have been proposed
in the literature [10] and have already guided research in
countries such as the US and Australia [13]. In Europe,
such criteria should be developed in a consensual process
with stakeholders while taking into account the clinical
and economic relevance of any research proposal.
Although we were successful in finding a definition of
CAM that fits well into the medical tradition of the EU
countries included in the CAMbrella project [11], a valid
and comprehensive taxonomy with clear definitions of
different CAM procedures still needs to be developed
internationally within a transparent consensus process.
Until then, CAM researchers must provide study partici-
pants and the scientific community with clear descrip-
tions of their understanding of CAM.
Strategic implications
In order to achieve CAMbrella’s vision, there is need for
stronger institutional support of CAM research. So far,
Europe has lagged behind North America, Asia and
Australia in terms of structural research funding in
CAM [13,15]. A lack of institutional support at the
European level has resulted in the fragmented picture of
CAM described in CAMbrella. Indeed, research funding
to date has been driven mainly by particular interests
from stakeholders such as patient interest groups or
CAM providers. Increased institutional support at the
European level is needed to promote research on the
topics proposed in the roadmap and to ensure methodo-
logical quality.
We recommend first establishing a European CAM re-
search coordination office to foster systematic communi-
cation between EU governments, the public, charitable
and industry funders, researchers, and other stake-
holders. Its aim would be to inform the public about re-
cent developments in CAM research, and to disseminate
information about research strategy developments and
funding among researchers.We propose an EU-funded European Centre for CAM
(ECCAM) comparable to the National Center for Com-
plementary and Alternative Medicine (NCCAM) at the
National Institutes of Health in the US. This depends on
the generation of political will at the EU and member
state level. The aim of the centre would be to stimulate
and support high-quality research on CAM in the EU
through an independent research strategy aligned with
EU health policy and through its own capacity to fund
projects and fellowships. We also recommend improving
the quality of CAM research by investing in education,
training and collaboration in the CAM research commu-
nity across Europe and beyond.
Summary
Although the volume of research into CAM in Europe
has increased over the past two decades, there are still
insufficient data on the prevalence, effectiveness, effi-
cacy, safety and health economic benefits of most CAM
treatments. As a result, patients, providers and other
stakeholders are unable to access rigorous and reliable
evidence on CAM. We have put forward a roadmap for
a strategic research policy to address this deficiency and
create a foundation for informed decisions. Our recom-
mendations are based on extensive systematic reviews
investigating the current state of CAM in the EU and
were shaped in collaboration with key international
stakeholders and CAM research experts in a transparent
and structured manner.
CAMbrella recommends that we develop:
 reliable knowledge about the provision and use of
CAM in the EU, especially with regard to national
differences;
 real-world knowledge to help patients and health
care providers decide when CAM treatment is
appropriate; and
 knowledge about the EU public’s interest in CAM,
especially regarding different models of CAM and
conventional health care integration, and the
implementation of this interest in the research
agenda.
CAM research must use generally accepted and appro-
priate research methods to build a solid evidence base.
These include quantitative and qualitative approaches,
particularly in mixed-methods studies.
The CAMbrella research roadmap reflects international
trends in research [13]. It can be compared to the latest
NCCAM strategic plan “Exploring the Science of CAM:
Third Plan 2011-2015” [27], whose five main objectives
are (1) to advance research on mind and body interven-
tions, practices and disciplines, (2) advance research on
CAM natural products, (3) increase understanding of
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tegration into health care and health promotion, (4) to im-
prove the capacity of the field to carry out rigorous
research and (5) to develop and disseminate objective,
evidence-based information on CAM interventions. Ob-
jectives 3 to 5 are comparable to the research focus in
CAMbrella, with its strong emphasis on CAM research in
real-world settings and the development and improve-
ment of research capacity. Importantly, however, CAM-
brella pays special attention to the situation in the EU.
The lack of data on CAM prevalence and provision, as
well as the diversity of the EU public’s interests in CAM,
are central aspects of the CAMbrella roadmap.
The CAMbrella research roadmap identified core
areas to evaluate CAM within the EU systematically
using generally accepted research methodology, includ-
ing mixed-methods designs. A robust research strategy
depends on the funding of a European CAM coordinat-
ing research office and of a European Centre for CAM
to realize the CAMbrella research roadmap and enhance
clinical knowledge. We are confident that the sugges-
tions put forward in the roadmap can guide CAM re-
search so that it will make a stronger contribution to the
needs of the public, health care payers and health care
providers in Europe.
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